In resistant cells, the overall effect of the PTX-Elacridar combined treatment was inhibitory of tumor growth, nevertheless these combined drugs determined a nuclear accumulation of TUBβIII, as well as the induction of pro-angiogenic genes (VEGFA, VEGFC, Ang2). This evidence concerns the gene VEGFC and neoplasm.